The generic name of Neovusin is recombinant human brain natriuretic peptide for injection, which has the efficacy and effect of improving the symptoms of dyspnea as well as systemic symptoms in patients with heart failure.
1. Recombinant human brain natriuretic peptide for injection can reduce the anterior and posterior cardiac load, increase cardiac output, and have a rapid reduction in the degree of dyspnea and systemic symptoms in patients with heart failure, and is suitable for intravenous use in the treatment of dyspnea at rest or during light activity in patients with acute decompensated stage of heart failure NYHA classification > class II.
2. Contraindications include patients who are allergic to the product, patients with systolic blood pressure <90mmHg or cardiogenic shock, and should be avoided in patients suspected of having or known to have low cardiac filling pressures.
3. Hypotension is the most common adverse reaction after the use of the drug, and other adverse reactions are mostly characterized by ventricular tachycardia, elevated blood creatinine, headache, nausea and so on.
Specific medication matters should be carried out under the guidance of a specialist, not unauthorized use of drugs.